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ABSTRACT
At present, several procedures are used for staging liver fibrosis.
However, these methods may involve clinical complications and/or
present diagnostic uncertainty mainly in the early stages of the
disease. Thus, this study was designed to unveil new non-invasive
biomarkers of liver fibrosis in an in vivo model of fibrosis/cirrhosis
induction by CCl4 inhalation by using a label-free quantitative LC-MS/
MS approach. We analyzed 94 serum samples from adult Wistar rats
with different degrees of liver fibrosis and 36 control rats. Firstly,
serum samples from 18 CCl4-treated rats were clustered into three
different groups according to the severity of hepatic and the serum
proteome was characterized by label-free LC-MS/MS. Furthermore,
three different pooled serum samples obtained from 16 control Wistar
rats were also analyzed. Based on the proteomic data obtained, we
performed a multivariate analysis which displayed three main cell
signaling pathways altered in fibrosis. In cirrhosis, more biological
imbalances were detected as well as multi-organ alterations. In
addition, hemopexin and signal-induced proliferation-associated 1
like 1 (SIPA1L1) were selected as potential serum markers of liver
fibrogenesis among all the analyzed proteins. The results were
validated by ELISA in an independent group of 76 fibrotic/cirrhotic rats
and 20 controls which confirmed SIPA1L1 as a potential non-invasive
biomarker of liver fibrosis. In particular, SIPA1L1 showed a clear
diminution in serum samples from fibrotic/cirrhotic rats and a great
accuracy at identifying early fibrotic stages. In conclusion, the
proteomic analysis of serum samples from CCl4-treated rats has
enabled the identification of SIPA1L1 as a non-invasive marker of
early liver fibrosis.
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INTRODUCTION
The identification of non-invasive markers of fibroproliferative
processes has been subject of considerable investigation during the
last decade (Fernandez-Varo and Jimenez, 2011; Martinez et al.,
2011a). The huge burden of these pathologies and the availability of
next-generation antifibrotic drugs allowing early therapeutic
interventions have been major drivers in achieving this goal.
Despite these efforts, however, the challenge remains elusive. The
natural history of most liver diseases is probably among the major
reasons accounting for this. Liver diseases are usually an insidious
process that may evolve for long periods of time and may develop
without evident clinical manifestations during the first years of
evolution after the onset of injury (Hernandez-Gea and Friedman,
2011; Hannivoort et al., 2012). Under this scenario, the search for
fibroproliferative processes has become endless. In the current
investigation we attempted to circumvent this difficulty by unveiling
circulating biomarkers of liver fibrosis in rats with carbon
tetrachloride (CCl4)-induced fibrosis. In this experimental model
the time to detect histological signals of hepatic healing is
considerably shortened and it also allows the collection of tissue
samples, blood and clinical data at different points of disease
evolution (Clària and Jiménez, 2005). This experimental approach
was combined with a label-free liquid chromatography-tandem
mass spectrometry (LC-MS/MS) workflow in a large set of serum
samples obtained from fibrotic rats and healthy animals. Label-free
quantitative LC-MS/MS is a powerful method for identifying and
quantifying proteins in complex samples (Altelaar et al., 2013;
Sandin et al., 2015). This pilot study was initially performed for
biomarker candidate selection and was followed up with enzyme-
linked immunosorbent assay (ELISA) validation of two biomarkers
in a larger sample cohort. Following this discovery protocol, we
were able to uncover signal-induced proliferation-associated 1 like 1
(SIPA1L1) as a new non-previously described early biomarker of
liver fibrosis in CCl4-treated rats, thus providing scientific rational to
design clinical studies assessing the diagnostic and/or prognostic
utility of SIPA1L1 in patients with liver fibrosis.
RESULTS
On histological examination, fibrotic lesions evolved from a weak
deposition basically in the portal area (mild fibrosis) to several
thicker septa which resulted from more prolonged exposure to
CCl4 (severe fibrosis). Finally, most of the animals exposed to
CCl4 for longer periods of time developed cirrhosis, and the
histological analysis displayed the formation of regenerative
nodules of liver parenchyma separated by fibrotic septa
(Fig. S1). Control CCl4 non-treated rats displayed no appreciable
alterations in liver histology and an almost negligible amount of
fibrous tissue. Table 1 shows serum electrolytes and the
biochemical tests of liver function in control and CCl4-treated
rats included in the training group. As expected, fibrotic and
cirrhotic rats included in this group had important and progressive
alterations in liver-function tests, being more pronounced in
cirrhotic animals.
Proteomic signature of CCl4-treated rats and signaling
pathway analysis
To determine if there is a clustering of observations suggesting an
underlying multivariate pattern of proteins, a principal component
analysis (PCA) was performed. The 45 most discriminatory
proteins, as reflected by the highest statistical significance whenReceived 4 April 2016; Accepted 5 May 2016
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compared to control samples, were included in the analysis
(Table S1). No differences were observed among fibrotic rats
regardless of the presentation of mild/moderate or severe fibrosis.
However the scatter plot visually conveys the separation of fibrotic,
cirrhotic and control rats with no overlapping among samples
(Fig. 1). Afterwards, two quantitative signaling pathway analyses
were performed based on all the proteins identified and quantified
(Fig. 2). Clear alterations in the coagulation cascade (coagulation
system and intrinsic prothrombin activation pathway) as well as
variations in the acute phase response signaling were found. The
regulation of proliferative signaling was also affected in the fibrotic
group (Fig. 2A). As expected, the cirrhosis signaling pathway
analysis showed more anomalies. Apart from those observed in
fibrosis, other alterations such as the G-protein coupled receptor
signaling pathway or the cAMP-mediated signaling were also
statistically significant, among others (Fig. 2B). Finally, several
pathological mechanisms were detected in both the fibrotic
(Fig. 2C) and cirrhotic groups (Fig. 2D), mainly related to the
liver disease. Of note was that pathways related to cardiac damage or
renal dysfunction were also affected in the group of cirrhotic rats
thus reinforcing the confidence of the performed analysis.
Hemopexin and SIPA1L1 as potential serum biomarkers for
fibrosis and cirrhosis detection
The ten different protein peaks showing the most statistically
significant expression in samples from CCl4-treated rats as
compared to controls were selected. Among these, four were
specifically detected in samples from fibrotic animals whereas six
were exclusively found in cirrhotic rats (Table 2). Only proteins
showing at least a twofold change in expression were further
considered for subsequent analysis. Moreover, high-abundant
serum proteins and proteins not very conserved between rats and
humans were also excluded. According to this data processing
strategy, only SIPA1L1 and hemopexin were selected. In particular,
SIPA1L1 was down expressed in fibrosis whereas hemopexin was
increased in cirrhosis. Representative MS/MS spectra from the
SIPA1L1 and hemopexin peptides are shown in Fig. 3.
Biomarker assessment in the validation group
To confirm that SIPA1L1 and hemopexin were potential
biomarkers for the detection of liver fibrosis and cirrhosis
respectively, both candidates were measured by ELISA in a large
validation group of CCl4-treated rats with different degrees of
liver fibrosis. Table 3 shows systemic and portal hemodynamics,
serum electrolytes and standard parameters of liver function in all
animals included in the validation protocol. Paralleling the
results found in the training protocols, CCl4-treated rats showed a
progressive deterioration of hepatic enzymes and liver function
as fibrosis evolved, which was also associated with a gradual
decrease in mean arterial pressure (MAP) and increased portal
pressure (PP).
As shown in Fig. 4A, no differences were detected in the
circulating levels of hemopexin between control and CCl4-treated
rats, including cirrhotic animals. These results, therefore, failed to
confirm hemopexin as a non-invasive biomarker of liver fibrosis/
cirrhosis in rats. In contrast, CCl4-treated rats with mild fibrosis
showed a significant reduction in the serum concentration of
SIPA1L1 as compared to controls. These results were coincident to
those found in the label free quantitative LC-MS/MS analysis.
Furthermore, this diminution was also observed in rats with severe
fibrosis and cirrhosis (Fig. 4B).
Accuracy of SIPA1L1 and hemopexin to detect early stages
of hepatic fibrosis and cirrhosis, respectively
The results for the accuracy of SIPA1L1 and hemopexin in fibrotic
and cirrhotic rats are presented as receiver-operating characteristic
(ROC) curves in Fig. 5A. Animals belonging to the fibrotic groups
(n=50) were considered in the analysis for SIPA1L1, whereas only
cirrhotic rats were considered at assessing hemopexin (n=17). The
ROC of SIPA1L1 showed an excellent diagnostic accuracy to
Table 1. Baseline characteristics of all the rats included in the training set
Fibrosis
Control (n=16) Mild/moderate <6% (n=6) Severe 6-11% (n=6) Cirrhosis >11% (n=6)
Body weight (g) 437±11 375±17 363±11* 360±15*
K+ (mM) 5.8±0.1 5.8±0.2 5.6±0.3 5.6±0.2
Na+ (mM) 143±0.3 144±0.4 143±0.5 142±0.9
Creatinine (mg/dl) 0.51±0.01 0.52±0.00 0.48±0.03 0.41±0.01**
Alanine aminotransferase (U/l) 51±1 78±13 111±19 151±20***
Aspartate aminotransferase (U/l) 94±15 271±113 576±162** 1129±202***
Gamma-glutamyltransferase (U/l) 0.83±0.29 0.17±0.10 2.57±1.95 12.27±2.32**
Albumin (g/l) 35.5±0.4 35.5±0.6 34.5±1.0 30.0±0.9**
Total proteins (g/l) 62.3±1.7 59.5±4.5 58.4±2.0 41.2±1.2***
Total bilirubin (mg/dl) 0.0±0.0 0.0±0.0 0.2±0.1 2.3±0.4***
*P<0.05, **P<0.01, ***P<0.001 in comparison to control group (Kruskal–Wallis test with Dunn post hoc test). Results are given as mean±s.e.m.
Fig. 1. Multivariate data analysis of serum samples from CCl4-
treated rats and the control group. PCA of the serum proteomic data
obtained from CCl4-treated and control rats. Only the first two principal
components were plotted. The score plot displayed a clear separation
between the control, fibrotic and cirrhotic groups, despite no differences
being observed between mild/moderate fibrosis and severe fibrosis.
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discriminate rats with fibrosis from control animals [area under
the ROC (AUROC): 0.865, P<0.0001]. In contrast, the ROC of
hemopexin to discriminate cirrhotic from control rats displayed a
considerably lower diagnostic efficacy (AUROC: 0.702), which
lacked statistical significance. In addition, a serum concentration of
SIPAL1L1 of 475.5 pg/ml was selected as the optimal cutoff value
to differentiate normal from fibrotic animals. This estimation was
based on the maximum value of the likelihood ratio, which
minimizes the number of false positive and false negative cases.
Above this cutoff, 86% of rats did not show significant fibrosis.
Below this cutoff, 97% of rats had fibrosis. In addition, we correctly
classified 74% of the animals with fibrosis. Finally, the specificity
was also determined and reached the 95% (Fig. 5B).
DISCUSSION
Early detection of fibrosis progression is an essential step for
preventing future clinical complications in patients with chronic
liver disease. At present, liver biopsy is still the gold standard
procedure to assess hepatic fibrosis (Fernandez-Varo and Jimenez,
2011; Castera and Pinzani, 2010), but the risk of clinical
complications and sampling errors are some of the most
remarkable limitations (Martinez et al., 2011a; Cadranel et al.,
2000; West and Card, 2010). In this context, new non-invasive
biomarkers have recently appeared as potential alternatives to liver
biopsy. However, early detection of hepatic fibrosis remains an open
challenge, as the diagnostic capacity of many circulating markers
and algorithms are not as accurate in the early and mild stages of
liver fibrosis in comparison to advanced fibrosis (Lichtinghagen
et al., 2013; Martinez et al., 2011b). In most cases the slow
progression of the disease emerges as one of the main obstacles for
discovering specific biomarkers of early fibrosis.
In the present study this difficulty was circumvented using a
strategy for identifying biomarkers of liver fibrosis in an
experimental model of rats with CCl4-induced fibrosis and
cirrhosis that closely reproduces the histological, hemodynamic,
biochemical and renal disturbances that patients with liver disease
develop. Actually, previous investigations from our laboratory and
others have demonstrated that these animals have a gradually
increased hepatic deposition of collagen fibers which is associated
with a progressive derangement in systemic and splanchnich
hemodynamics, altered serum concentrations of liver and renal
function tests and marked sodium and water retention that results in
ascites formation (Clària and Jiménez, 2005). This sequence of
events is very similar to that observed in human cirrhosis and lays
the foundation to use this model to better understand the
pathophisiological mechanisms involved in these phenomena, as
well as to evaluate the therapeutic utility of new drugs to ultimately
be used in patients with liver disease (Fernández-Varo et al., 2016;
Oró et al., 2016). The results found in the training and validation
groups further confirm this contention. In fact, collagen deposition
in the CCl4-treated rats ranged between 1.9% and 26.3% according
to the time submitted to the fibrosis induction protocol. We also
observed a progressively decreased MAP and increased PP.
Moreover, low serum concentrations of albumin and marked
activation of hepatic enzymes were also noted. Finally, ascites
was detected in some of the animals with higher hepatic collagen
content. All these data confirm the suitability of the experimental
model to uncover new biomarkers of liver fibrosis.
Two-dimensional gel electrophoresis (2-DE) has been the most
widely used proteomic method for comparing protein expression
profiles between normal and pathological conditions (Srinivas et al.,
2001; Adam et al., 2001). However, the 2-DE approach has several
disadvantages, including the difficulty in separating proteins with
Fig. 2. Signaling pathway analysis. The comparisons of the cell
signaling pathways (A,B) and the pathological mechanisms (C,D)
occurring in fibrotic (A,C) and cirrhotic rats (B,D) were modeled
using the Ingenuity Pathways Knowledge Base (IPA). The
proteomic results obtained in control, fibrotic and cirrhotic rats
were comparedwith global molecular networks using the Fisher’s
Exact Test. The resulting P-values were adjusted for multiple
comparisons using the Benjamini and Hochberg’s method to
control the false discovery rate. After multitest adjustment,
differences were considered to be significant at P<0.05. The red
line across the cell signaling graphs delimits the point where
P=0.05. In addition, the significance of the association was
measured on the basis of the ratio of the number of targets from
the data set that map to the pathway divided by the total number
of targets that are included in the canonical pathway (yellow line
and right axis, top panels). Only proteomic changes larger than
twofold were included in the pathway analysis.
Table 2. Log fold-change of the potential biomarkers of liver fibrosis
and cirrhosis
Symbol Protein name Log fold change
Biomarkers of fibrosis
APCS amyloid P component −1.3
AZGP1 alpha-2-glycoprotein 1 4.8
FN1 fibronectin 1 −2.4
SIPA1L1 signal-induced proliferation-












SERPING1 serpin peptidase inhibitor, clade
G (C1 inhibitor), member 1
−1.3
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extremes in molecular weight (<10 kDa or >200 kDa) and in
isoelectric points (<4 or >10) as well as complications for resolving
hydrophobic proteins or even detecting low abundance proteins
(Rabilloud, 2002; Braun et al., 2007). To overcome these
drawbacks, label-free LC-MS/MS has become indispensable in
the proteome analysis of several diseases (Altelaar et al., 2013)
including kidney chronic allograft dysfunction and hematological
malignances (Quintana et al., 2009; Casado et al., 2013).
Furthermore, this technique has emerged as a promising
alternative for biomarker discovery (Sandin et al., 2015).
Compared to the protein-labeling approaches, label-free
quantitative methods allow individual analysis of each sample,
enabling the study of a large number of specimens for each
experiment due to the absence of labeling restrictions. Data analysis,
encompassing protein identification and quantification provides a
general overview of all the proteomic data obtained from the MS
assessment. In the current investigation multivariate PCA was
adopted to explore and visualize a protein biomarker fingerprint
associated with hepatic fibrosis. Following the identification of the
45 peaks showing higher statistical difference between fibrotic and
control samples in the definition/training groups, the PCAwas able
to distinguish a different protein signature for fibrotic, cirrhotic and
Fig. 3. MS/MS analysis of the SIPA1L1 and hemopexin peptides identified. (A) Amino acid sequencing of SIPA1L1 and hemopexin. (B,C) Representative
MS/MS spectra of the peptides identified from SIPA1L1 (B) and hemopexin (C).
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control samples. Interestingly enough, this proteomic analysis did
not establish clear differences between rats with mild/moderate or
severe fibrosis. A subsequent analysis performed by clustering all
the proteomic data into the different cell signaling pathways pointed
out three major altered signaling pathways in the fibrotic animals,
i.e. the acute phase response, the coagulation cascade and
mechanisms involved in cell proliferation. As anticipated, the
amount of deregulated signaling pathways in cirrhotic animals was
higher and affected other organs than the liver, such as kidney and
heart. These findings are in concordancewith the most characteristic
pathological features already described in patients with different
degrees of alteration in hepatic architecture (Mercer and Chambers,
2013; Betrosian et al., 2007; Møller and Henriksen, 2002), thus
further validating the usefulness of CCl4-treated rats in biomarker
discovery for liver disease.
Label free LC-MS/MS proteomic analysis resulted in the
identification of two non-invasive independent circulating
proteins, SIPA1L1 and hemopexin, biomarkers of fibrosis and
cirrhosis, respectively. Three isoforms of SIPA1L1 of
approximately 200 kDa have been described (Gao et al., 1999).
At present, SIPA1L1 is known to be a GTPase-activating protein
(GAP) as it possesses a region of homology with GAP domains
(Gao et al., 1999). On the other hand, SIPA1L1 has also been
described as a potential tumor suppressor (Gao et al., 1999) since it
is located on a region in chromosome 14 which has been reported to
exhibit a loss of heterozygosity in malignant meningiomas (Menon
et al., 1997). Thus, it seems that its inactivation contributes to
malignant transformations. In the current investigation, we observed
a significant diminution of SIPA1L1 serum levels in mild/moderate
fibrosis and this reduction was maintained over the fibrotic and
cirrhotic groups. Furthermore, SIPA1L1 amino acid sequence is
highly conserved between humans and rats. In particular, and
according to the GeneCards database, the similarity reaches the
95.34% of coincidence. Therefore, it is feasible to think that the
results obtained from the in vivomodel could be translated to human
liver fibrosis, since proteins with very similar amino acid
composition and sequence often implies similar functions
(Alberts et al., 2007; Lodish et al., 2000). Hemopexin is a 60 kDa
glycoprotein which has been shown to be mainly expressed in the
hepatic parenchymal cells (Thorbecke et al., 1973). It belongs to the
acute-phase protein family, whose synthesis is induced by several
cytokines in response to an inflammatory event (Baumann and
Gauldie, 1994). In addition, hemopexin is the circulating protein
with the highest affinity for heme, and it is considered to be the
major responsible for its transport (Tolosano et al., 1999). This
feature has led to the belief that hemopexin prevents the body from
heme-catalyzed oxidation as well as heme-bound iron loss, thus
protecting against inflammation and liver fibrosis (Tolosano et al.,
1999). Our results in the training group showed a significantly
increased serum concentration of hemopexin in cirrhotic rats as
compared to control animals.
The results obtained in the validation group confirmed SIPA1L1
as a biomarker but failed to demonstrate that hemopexin is an
appropriate indicator of cirrhosis in rats. In fact, assessment of the
serum concentration of hemopexin by ELISA in the different groups
of CCl4-treated rats, including cirrhotic animals, did not show
significantly different values as compared to control animals.
Accordingly, the diagnostic accuracy of this parameter, as assessed
by the ROC curve, failed to show statistical significance. By contrast
SIPA1L1 does demonstrate excellent diagnostic accuracy for
Table 3. Baseline characteristics of all the rats included in the validation group
Fibrosis
Control (n=20) Mild/moderate <6% (n=25) Severe 6-11% (n=25) Cirrhosis >11% (n=26)
Body weight (g) 463±15 410±8* 440±12 428±12
HR (bpm) 398±9 387±7 388±9 355±6***
PP (mmHg) 5.8±0.1 7.9±0.5** 9.2±0.6*** 12.3±0.5***
MAP (mmHg) 123±1 119±2 109±3** 87±3***
SPP (mmHg) 117±1 111±2 100±3*** 75±3***
K+ (mM) 5.5±0.1 5.2±0.2 4.4±0.1*** 4.6±0.3***
Na+ (mM) 143±1 141±1 143±1 141±1
Creatinine (mg/dl) 0.55±0.01 0.60±0.04 0.59±0.04 0.47±0.03
Alanine aminotransferase (U/l) 42±2 394±62*** 365±71*** 336±63***
Aspartate aminotransferase (U/l) 88±4 240±27** 403±86*** 573±65***
Gamma-glutamyltransferase (U/l) 0.24±0.15 1.17±0.43 2.60±0.77** 5.64±0.91***
Albumin (g/l) 36.7±0.6 30.0±0.8*** 29.7±0.8*** 26.9±0.7***
Total proteins (g/l) 63.9±1.5 52.3±1.9*** 52.7±1.2** 47.1±1.2***
Total bilirubin (mg/dl) 0.0±0.0 0.1±0.1 0.3±0.1*** 1.7±0.2***
**P<0.01, ***P<0.001 in comparison to control group; (one-way ANOVAwith Newman–Keuls post hoc test or Kruskal–Wallis test with Dunn post hoc test when
appropriate). Results are given as mean±s.e.m.
Fig. 4. Serum concentration of hemopexin and SIPA1L1 in
CCl4-treated rats. (A) Serum hemopexin values obtained
from control (n=15), mild/moderate (n=15), severe fibrotic
(n=15) and cirrhotic rats (n=17). One-way ANOVA with
Newman–Keuls post hoc test was used to evaluate
dissimilarities between groups. No differences were found
between groups. (B) SIPA1L1 serum levels in control rats
(n=20), mild/moderate (n=25) and severe fibrotic rats (n=25)
and cirrhotic (n=26). Differences between groups were
evaluated by the Kruskal–Wallis test with the Dunn post hoc
test. *P<0.05, ***P<0.001 in comparison to the control group.
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fibrosis, being more remarkable when evaluating samples from rats
with mild/moderate fibrosis (data not shown). In fact, the serum
concentrations of SIPA1L1 in this group of animals showed an
approximately 40% reduction in comparison to healthy animals.
Therefore, a reduction of SIPA1L1 serum concentration could
detect the early fibrotic subjects who are prone to develop more
severe complications and allow prompt therapeutic interventions.
Despite no studies having described the potential role that this
protein may have in liver fibrosis, a previous investigation (Tsai
et al., 2007) demonstrated that Wnt signaling affects the
phosphorylation and stability of SIPA1L1. In particular, Wnt
signaling activates casein kinase I epsilon (CKIε) (Swiatek et al.,
2004), which induces SIPA1L1 phosphorylation and its degradation
as well as the accumulation of β-catenin (Gao et al., 2002). Since the
Wnt signaling pathway is activated during liver fibrosis in hepatic
stellate cells (Miao et al., 2013) it is tentative to speculate that
SIPA1L1 diminution is a consequence of the activation of the
fibrogenic process. In this regard, several investigations have shown
that sustained Wnt/β-catenin pathway activation is linked to the
pathogenesis of different fibrotic disorders including liver fibrosis
(Cheng et al., 2008, 2010; He et al., 2009; Jiang et al., 2006; Li et al.,
2011; Myung et al., 2007). Therefore, these results are consistent
with the hypothesis that SIPA1L1 downregulation is a surrogate
marker of early fibrogenesis activation in liver disease. However,
the detailed mechanism by which this phenomenon could happen
still needs to be elucidated.
The current investigation took advantage of the in vivo model of
fibrosis induction by CCl4 inhalation in Wistar rats to identify
potential new biomarkers related to liver fibrosis progression. Using a
label-free LC-MS/MS proteomic approach, we performed
bioinformatics analyses to explore and visualize a protein biomarker
fingerprint associatedwith hepatic fibrosis. Subsequently,we selected
the 10 proteins with the greater discriminatory power between fibrosis
or cirrhosis and the control group. Among them, hemopexin and
SIPA1L1 were picked for further validation. Despite hemopexin
failing to demonstrate its value as an indicator of cirrhosis, SIPA1L1
showed a clear serum diminution and a great accuracy at identifying
early fibrotic stages in the validation group. This study, therefore,
strengthens the importance of combining reliable experimental
models with holistic proteomic approaches to uncover new
biomarkers of fibrosis in liver disease.
MATERIALS AND METHODS
Animal studies
The study was performed in 94 male adult Wistar fibrotic/cirrhotic rats and
36 control Wistar rats (Charles-River, Saint Aubin les Elseuf, France). The
design of the study was two folded: firstly, using quantitative label-free
LC-MS/MS we assessed a possible correlation between fibrosis stage and
serum proteomic expression in a training group of 18 rats with different
degrees of fibrosis. Sixteen rats were used as the control group. At the end of
the study, the animals were sacrificed by isofluorane overdose and serum
samples from each rat were obtained and kept at −80°C until further
analysis. Afterwards, to validate the usefulness of the biomarkers identified
in the training protocol, two different quantitative enzyme immunoassays
(ELISA) were performed in a validation set of 76 CCl4-treated rats and 20
healthy animals. Standard liver and renal function tests were also analyzed
in all animals.
Induction of fibrosis and cirrhosis in rats
Fibrosis was induced by repetitive CCl4 inhalation as described previously
(Clària and Jiménez, 2005). Briefly, rats were fed ad libitum with standard
chow and water containing 0.3 g/l of phenobarbital as drinking fluid.
Animals were exposed to a CCl4 vapor atmosphere twice a week, starting at
30 s per exposure. The duration of the inhalation was increased by 30 s after
the first three sessions and by 1 min after every other three sessions until it
reached a plateau of 5 min. To obtain variable degrees of hepatic fibrosis,
CCl4-treated rats were investigated between the 9th and the 40th week after
starting the fibrosis-induction protocol. Control rats were studied after
similar periods of phenobarbital administration alone.
Hemodynamic studies
Systemic and portal hemodynamics was assessed in 76 CCl4-treated rats and
20 control rats as described elsewhere (Reichenbach et al., 2012). In short,
animals were anesthetized with Inactin (50 mg/kg body weight; Sigma-
Aldrich, St. Louis, MO, USA) and a catheter was implanted in the right
femoral artery. Hemodynamic parameters were allowed to stabilization for
30 min, and the mean arterial pressure (MAP) and heart rate (HR) values
were registered for two periods of 30 min. Each value shown in Table 3
represents the average of these two measurements. Subsequently, an
abdominal incision was performed, and another catheter was placed in the
portal vein through the ileocolic vein and fixed to the mesentery with
cyanoacrylate glue. After verifying free blood reflux, portal pressure (PP)
was registered. Splanchnic perfusion pressure (SPP) was estimated as MAP-
PP. At the end of the study, animals were sacrificed and serum and liver
tissue samples were obtained and kept as described in the ‘Animal studies’
section.
Quantification of fibrosis
Four-micron-thick sections of paraffin-embedded liver were stained in 0.1%
Sirius Red F3B (Sigma-Aldrich) in saturated picric acid (Sigma-Aldrich).
The relative fibrosis area, expressed as a percentage of the total liver area,
was evaluated by analyzing a minimum of 30 fields of Sirius Red-stained
liver sections per animal. Each field was acquired at 10× magnification
(Eclipse E600; Nikon, Kawasaki, Kanagawa, Japan), and the images
Fig. 5. Diagnostic accuracy of hemopexin and SIPA1L1 and diagnostic
tests of SIPA1L1. (A) Diagnostic accuracy of hemopexin and SIPA1L1 to
differentiate cirrhosis and fibrosis, respectively. When using the hemopexin
serum concentration, the AUROC was 0.702 but not statistically significant
(P>0.05). The AUROC obtained from SIPA1L1 serum concentration was
0.865 and statistically significant (P<0.0001). (B) Several diagnostic tests
(Sensitivity, Specificity, NPV and PPV) were performed in SIPA1L1 after
determining 475.5 pg/ml as the optimal cutoff.
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obtained were analyzed using ImageJ software (version 1.47; NIH).
According to the percentage of fibrosis area the histological lesion was
classified as mild/moderate fibrosis (<6%), severe fibrosis (6-11%) or
cirrhosis (>11%).
Label-free LC-MS/MS proteomics and bioinformatic analysis of
the results
Pooled samples from rats with mild (n=6) or severe fibrosis (n=6) and
cirrhosis (n=6) were fractionated using Seppro IgY7 LC10 columns
(Genway Biotech Inc., USA) in order to remove the seven most abundant
serum proteins (albumin, IgG, fibrinogen, alpha-1-antitrypsin, haptoglobin,
transferrin and IgM). In addition, three pools of samples from 5, 5 and 6
control rats were also prepared and fractionated as described. After
fractionation, 20 μg of total protein from each pool were digested. The
organic solvent of the sample was evaporated in a Savant SpeedVac
concentrator (Thermo Fisher Scientific, Waltham,MA, USA), and the pellet
was redissolved in 20 μl 8 M urea/0.4 M ammonium bicarbonate. Proteins
were reduced after incubation with 2 μl of 45 mM dithiothreitol (DTT) and
alkylated after incubation with 2 μl of 100 mM iodoacetamide. Then, the
samples were digested with 2 μg of Lys C 0.1 mg/ml for 4 h and 2 mg of
trypsin 0.1 mg/ml for 12 h. Digested proteins were evaporated and the
peptides were dissolved in 5 μl 70% formic acid+25 μl 0.1% trifluoroacetic.
Five microliters of each experimental sample at the same peptide
concentration were injected on a LTQ Orbitrap Velos (Thermo Fisher
Scientific) through a nanoAcquity ultra performance liquid chromatography
(UPLC) (Waters Corporation, Mildford, MA, USA) system equipped with a
Water Symmetry C18 column (180 μm×20 mm). Trapping was done at
15 µl/min in the presence of 0.1% formic acid for 1 min. Peptide separation
was performed with a linear gradient over 90 min at a flow rate of
300 nl/min. Mass spectra were acquired using a maximum injection time of
900 ms followed by three data dependantMS/MS acquisitions in the ion trap
(with a precursor ions threshold of >3000). The total cycle time for both MS
andMS/MS acquisition was 2.4 s. Peaks targeted for MS/MS fragmentation
by collision-induced dissociation (CID) were first isolated with a 2 Da
window followed by normalized collision energy of 35%. Samples of each
experimental condition were injected in triplicate. The data were processed
using the Progenesis LC-MS (Nonlinear Dynamics, LLC), R (http://www.r-
project.org), Mascot (Matrix Science) and IPA programs (Ingenuity
Systems). Briefly, the original files with the results obtained from the
LTQOrbitrap were imported into Progenesis, and the spectra of the different
experimental conditions were aligned to minimize variability in
chromatographic retention times. No adjustments were necessary in the
m/z dimension due to the high mass accuracy of the spectrometer (<3 ppm).
Features within retention time ranges of 0-25 min and 110-120 min were
filtered out, as were features with a charge≥+8. The .mgf files generated in
Progenesis were analyzed using the Mascot algorithm based on SwissProt
rat data. The following parameters were set for theMascot algorithm: trypsin
enzyme, carbamidomethyl and oxidation for variable modifications,
monoisotopic for mass values, unrestricted protein mass, ±20 ppm for
peptide mass tolerance, ±0.6 Da for fragment mass tolerance, +7 for charge,
3 for max missed cleavages and ESI-TRAP for instrument type. We
considered a protein identified whenMascot listed it as significant and more
than two unique peptides matched the same protein. Search hits were
assigned to corresponding features using Progenesis LCMS software. The
data obtained were normalized by the method of robust quantile
normalization and statistical differences were assessed using linear models
and the moderate t-test (LIMMA package, Bioconductor) (Ritchie et al.,
2015). Subsequently, diseases, biological functions and canonical pathways
were studied using the Ingenuity Pathways Knowledge Base (Ingenuity
System Inc, USA). The proteomic results were compared with global
molecular networks using the Fisher’s Exact Test. The resulting P-values
were adjusted for multiple comparisons using the Benjamini and
Hochberg’s method to control the false discovery rate. After multitest
adjustment, differences were considered to be significant at a P-value less
than 0.05. For the canonical pathway analysis, the significance of the
association was additionally measured considering the ratio of the number of
significant targets that map to the pathway divided by the total number of
targets that are included in the canonical pathway. Multivariate data analysis
was performed using R. Finally, the GeneCards database (http://www.
genecards.org/) was used to check homologies between the rat and human
genes encoding for the proteins which were statistically significant among
all the different groups.
Biomarkers assessment in the validation group
The proteomic analysis resulted in the identification of two circulating
proteins, hemopexin and SIPA1L1 as the most promising biomarkers of
liver fibrosis in CCl4-treated rats. Next, the circulating levels of SIPA1L1
were measured by ELISA in an additional group of 76 CCl4-treated rats (25
rats with mild fibrosis, 25 rats with severe fibrosis and 26 rats with cirrhosis).
Hemopexin was also determined by ELISA in 47 of them (15 rats with mild
fibrosis, 15 rats with severe fibrosis and 17 rats with cirrhosis). 20 control
rats were included in the SIPA1L1 validation protocol, 15 of which were
also used in the hemopexin study. Hemopexin was measured according to
the manufacturer’s protocol (USCN Life Science Inc, Wuhan, China)
whereas SIPA1L1 reagents were obtained from EIAab (Wuhan, China), and
minor modifications of the manufacturer’s instructions were made. Briefly,
wells were incubated with either 100 μl of serum, standard dilution series or
standard diluent (blank) for 2 h at 37°C. After liquid removal, 100 μl of
biotin-conjugated polyclonal antibody were then added at a dilution of
1:100 and allowed to bind for 1 h at 37°C. Subsequently, well plates were
washed three times, and avidin conjugated to horseradish peroxidase (1:100
dilution) was incubated for 1 h at 37°C. The aspiration and wash processes
were repeated five times and 90 μl of substrate solution was added to each
well and allowed to bind for 20 min at 37°C, followed by the addition of
50 μl of 1 M H2SO4. Well plates were immediately read at 450 nm. The
optical density value obtained from the sample diluent was subtracted from
each standard determination. Subsequently, the standard curve was
generated. All were measured in duplicate. In addition, the SIPA1L1
ELISA kit assay was evaluated and obtained satisfactory results in the
dilution linearity test (range between 81.2% and 118.4%) as well as in the
recovery test (range between 89.3% and 109.8%). Furthermore, the intra-
assay (well to well) and inter-assay (plate to plate) coefficient of variation
(CV) were also determined, being of 6.09% and 7.51%, respectively.
Measurements and statistical analysis
Standard parameters of renal and liver function were measured using the BS-
200E Chemistry Analyzer (Mindray Medical International Ltd, Shenzhen,
China). The diagnostic accuracy of the different methods was analyzed by
constructing receiver-operating characteristic (ROC) curves andcalculating the
area under the ROC curve (AUROC). GraphPad Prism 5 (GraphPad Software,
Inc., San Diego, CA) was used for the analysis of the results, the development
of the ROC curve and the selection of the optimal SIPA1L1 cutoff value.
Statistical analysis were performed byone-way analysis of variance (ANOVA)
with Newman–Keuls post hoc test or Kruskal–Wallis test with the Dunn post
hoc test when appropriate, based on the results obtained from the D’Agostino
and Pearson omnibus normality test. Results are expressed asmean±s.e.m. and
P-values less than 0.05 were considered significant.
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